◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › M › MDXG

MiMedx Group Inc (MDXG) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-11-04

MiMedx Group Inc (MDXG) operates in the BIOTECHNOLOGY industry and is headquartered in Marietta, United States with about 808 employees. Its market capitalization is roughly $474 million. In the fiscal year ended 2025-12-31, MDXG reported $419M in revenue and $49M in net income.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

Interactive charts & full statements → Open the MDXG valuation workbench →

MDXG Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-09-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$303M	$419M	$349M	$321M	$268M	$242M	$248M	$359M	$359M	$321M	$245M	$187M	$118M	$59M	$27M	$8M	$1M	—	—	—	—
Gross Profit	$235M	$346M	$289M	$267M	$220M	$202M	$209M	$323M	$323M	$286M	$213M	$167M	$106M	$50M	$22M	$5M	($1M)	—	—	—	—
Gross Margin %	77.6%	82.6%	82.8%	83.0%	82.0%	83.6%	84.2%	89.9%	89.9%	89.0%	86.8%	89.2%	89.3%	84.2%	80.8%	59.4%	-118.0%	—	—	—	—
Operating Income (EBIT)	($25M)	$64M	$59M	$37M	($15M)	($7M)	($45M)	($4M)	($4M)	$46M	$1M	$24M	$7M	($3M)	($2M)	($10M)	($11M)	($12M)	($18M)	$0M	$0M
Operating Margin %	-8.2%	15.3%	16.9%	11.6%	-5.5%	-2.9%	-18.3%	-1.1%	-1.1%	14.4%	0.4%	13.0%	6.0%	-4.5%	-7.4%	-125.8%	-1335.1%	—	—	—	—
Net Income	($20M)	$49M	$42M	$67M	($30M)	($12M)	($49M)	($30M)	($30M)	$65M	$12M	$29M	$6M	($4M)	($8M)	($10M)	($11M)	($12M)	($17M)	$0M	$0M
Net Margin %	-6.6%	11.6%	12.2%	21.0%	-11.3%	-5.1%	-19.9%	-8.3%	-8.3%	20.2%	4.9%	15.7%	5.3%	-7.0%	-28.3%	-131.4%	-1447.6%	—	—	—	—
EBITDA	—	$83M	$65M	$41M	($11M)	($2M)	($38M)	$18M	$3M	$53M	$9M	$27M	$9M	($1M)	$0M	($8M)	($10M)	($11M)	($11M)	$0M	$0M
Earnings Per Share (EPS)	$-0.13	$0.32	$0.28	$0.46	$-0.27	$-0.11	$-0.46	$-0.28	$-0.27	$0.56	$0.11	$0.26	$0.05	$-0.04	$-0.09	$-0.14	$-0.19	$-0.32	$-3.00	$-0.01	$-0.00
Shares Outstanding (M)	—	150M	149M	146M	113M	110M	108M	106M	109M	116M	113M	114M	113M	96M	82M	72M	59M	—	6M	7M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$62M	$64M	$59M	$118M	$114M	$99M	$88M	$93M	$84M
Gross Profit	$50M	$44M	$42M	$99M	$95M	$80M	$72M	$76M	$69M
Gross Margin %	80.7%	69.0%	70.6%	83.9%	83.5%	81.0%	81.2%	81.8%	81.8%
Operating Income (EBIT)	($12M)	($18M)	($16M)	$21M	$22M	$12M	$8M	$11M	$11M
Operating Margin %	-19.4%	-28.7%	-27.2%	17.8%	19.5%	12.6%	9.3%	11.9%	13.3%
Net Income	($9M)	($15M)	($11M)	$15M	$17M	$10M	$7M	$7M	$8M
Net Margin %	-14.5%	-23.1%	-18.4%	12.9%	14.7%	9.8%	8.0%	8.0%	9.6%
EBITDA	—	($17M)	($14M)	$25M	$29M	$17M	$12M	$14M	$13M
Earnings Per Share (EPS)	$-0.06	$-0.10	$-0.07	$0.10	$0.11	$0.06	$0.05	$0.05	$0.05
Shares Outstanding (M)	—	148M	148M	150M	150M	149M	150M	149M	148M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Free Cash Flow History

Cash flow	TTM → 2026-09-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$21M	$74M	$66M	$27M	($18M)	($2M)	($39M)	$36M	$36M	$63M	$24M	$19M	$17M	$0M	($3M)	($7M)	($8M)	($9M)	($9M)	($8M)	$0M
Capital Expenditures (CapEx)	—	$1M	$2M	$2M	$3M	$3M	$2M	$9M	$9M	$5M	$6M	$6M	$3M	$2M	$1M	$0M	$0M	$0M	$0M	$1M	$0M
Free Cash Flow (FCF)	$14M	$73M	$65M	$25M	($21M)	($5M)	($42M)	$26M	$26M	$58M	$18M	$13M	$14M	($3M)	($4M)	($7M)	($8M)	($9M)	($9M)	($9M)	$0M
FCF Margin %	4.6%	17.4%	18.5%	7.7%	-7.7%	-2.1%	-16.8%	7.3%	7.3%	18.0%	7.2%	6.9%	12.0%	-4.4%	-14.7%	-92.1%	-1053.3%	—	—	—	—
Dividends Paid	—	—	—	$1M	$1M	$1M	$100M	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$4M	($10M)	$2M	$25M	$29M	$14M	$5M	$19M	$20M
Capital Expenditures (CapEx)	—	$1M	$1M	$0M	$4M	$0M	$0M	$0M	$5M
Free Cash Flow (FCF)	($1M)	($11M)	$1M	$25M	$25M	$14M	$5M	$19M	$14M
FCF Margin %	-1.6%	-16.7%	2.2%	20.8%	22.3%	14.4%	5.6%	19.9%	17.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Balance Sheet History

Balance sheet	2026-09-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$265M	$343M	$264M	$239M	$171M	$188M	$202M	$123M	$123M	$121M	$193M	$136M	$109M	$85M	$35M	$27M	$7M	$10M	$15M	$0M	$0M
Cash & Cash Equivalents	$121M	$166M	$104M	$82M	$66M	$87M	$96M	$45M	$45M	$27M	$34M	$28M	$47M	$44M	$7M	$4M	$1M	$3M	$7M	$0M	$0M
Total Liabilities	$54M	$86M	$71M	$96M	$97M	$95M	$111M	$73M	$73M	$47M	$60M	$28M	$20M	$11M	$15M	$15M	$1M	$4M	$1M	$0M	$0M
Total Debt (Short + Long-Term)	—	$19M	$20M	$50M	$50M	$49M	$49M	$66M	$0M	$0M	$0M	$0M	$0M	$0M	$4M	$5M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$211M	$257M	$193M	$143M	$75M	$93M	$91M	$50M	$50M	$74M	$133M	$108M	$89M	$74M	$20M	$12M	$6M	$6M	$14M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MDXG viewer.

Other Companies in BIOTECHNOLOGY

OVID · Ovid Therapeutics Inc — $496 million
CBIO · Crescent Biopharma, Inc. — $485 million
CAPR · Capricor Therapeutics Inc — $479 million
CTMX · CytomX Therapeutics Inc — $475 million
GYRE · Gyre Therapeutics Inc. — $471 million
OCS · Oculis Holding AG Ordinary shares — $470 million
MNPR · Monopar Therapeutics Inc — $469 million
PHAT · Phathom Pharmaceuticals Inc — $467 million

← MDX All “M” companies MDXH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.